---
title: "EXCLUSIVE: Sunshine Biopharma Secures Canadian Approval for Generic Hypertension Drug"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296358959.md"
description: "Sunshine Biopharma (NASDAQ:SBFM) secured Canadian regulatory approval for generic Enalapril tablets to treat hypertension, with shipments expected by late 2026 via subsidiary Nora Pharma. This expands its portfolio of 60 marketed drugs and aligns with the growing antihypertensive market. The announcement follows recent approvals for amoxicillin and a reverse stock split in June. SBFM shares rose 1.79% to $1.13 in premarket trading."
datetime: "2026-08-19T12:30:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296358959.md)
  - [en](https://longbridge.com/en/news/296358959.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296358959.md)
generator: "portal-rs"
---

# EXCLUSIVE: Sunshine Biopharma Secures Canadian Approval for Generic Hypertension Drug

**Sunshine Biopharma Inc.** (NASDAQ:SBFM) announced on Wednesday that it has secured regulatory approval to introduce its generic Enalapril tablets across the Canadian market, signaling a significant strategic step into first-line antihypertensive treatments.

The newly approved medication, the generic equivalent of the well-known brand *Vasotec*, will be available to patients in multiple dosage strengths: 2.5mg, 5mg, 10mg, and 20mg tablets.

Sunshine Biopharma currently markets 60 generic prescription drugs in Canada and plans to launch approximately 12 additional drugs during the remainder of 2026.

 **Read Also: EXCLUSIVE: Sunshine Biopharma Targets Canadian Market with New Women's Health Drug Approval** 

## Strategic Canadian Distribution

The pharmaceutical firm intends to leverage **Nora Pharma Inc**., its wholly owned subsidiary operating within Canada.

This dedicated division has already constructed a formidable, wide-reaching distribution infrastructure throughout the nation.

Through this established pipeline, retail pharmacies across Canada can expect to receive their initial shipments of the newly approved generic medication by the close of 2026.

## Tapping Into Antihypertensive Market

Sunshine said that, according to industry data, the worldwide antihypertensive drug sector was valued at a robust $25.94 billion in 2025.

Projections indicate this space will surge to an estimated $37.24 billion by the year 2034, registering a steady compound annual growth rate of 4.1%.

Furthermore, the broader Canadian pharmaceutical landscape itself represents approximately 2.1% of the total global industry, proudly standing as the sixth-largest individual market globally.

In May, Sunshine Biopharma received Canadian regulatory approval for generic amoxicillin as part of the expansion of its generic antibiotic portfolio.

The company said the product will be available in multiple dosage forms and strengths and is expected to be ready to ship to pharmacies in August 2026.

In June, the company concluded a one-for-ten reverse stock split to regain compliance with Nasdaq’s minimum bid price requirement for continued listing.

**SBFM Stock Price Activity**: Sunshine Biopharma shares were up 1.79% at $1.13 during premarket trading on Wednesday, according to Benzinga Pro data.

 **Read Also: Ross Gerber Rips Trump as Oil Soars: Iran Knows He Has ‘No Support’ Ahead of Midterms** 

*Harrison Jones / USA TODAY NETWORK via Imagn Images*

### Related Stocks

- [SBFM.US](https://longbridge.com/en/quote/SBFM.US.md)
- [SBFMW.US](https://longbridge.com/en/quote/SBFMW.US.md)

## Related News & Research

- [Sunshine Biopharma wins Canadian approval for generic Enalapril tablets](https://longbridge.com/en/news/296364575.md)
- [Sunshine Biopharma Announces ATM Equity Sales Agreement](https://longbridge.com/en/news/293253604.md)
- [BioAge Labs to present at Citi Biopharma Back to School Conference fireside chat](https://longbridge.com/en/news/297782949.md)
- [Redhill Biopharma Stock Doubles In One Session — Here's Why](https://longbridge.com/en/news/297531464.md)
- [Lexicon to present at Citi Biopharma Back to School investor conference](https://longbridge.com/en/news/297692441.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**